Compared with the control group, the group treated with erastin, a ferroptosis activator, showed a significant increase in the levels of Fe2+ in HCC cells, which was reversed by the overexpression of LINC00942 (Fig. 1D; p < 0.001, n = 3). The gene discussed is LINC00942; the disease is hepatocellular carcinoma.